On January 28, 2022, Candel Therapeutics, Inc. (the “Company”) removed Estuardo Aguilar-Cordova and Laura Aguilar from their roles as officers of the Company, without cause under their respective employment agreements with the Company, with such termination expected to be effective on February 7, 2022.
On January 28, 2022, Candel Therapeutics, Inc. (the “Company”) removed Estuardo Aguilar-Cordova and Laura Aguilar from their roles as officers of the Company, without cause under their respective employment agreements with the Company, with such termination expected to be effective on February 7, 2022.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 1.0
Laura Aguilar was removed as officer at Candel Therapeutics, Inc..
Action
removed
Role
officer
Exact text from the filing
On January 28, 2022, Candel Therapeutics, Inc. (the “Company”) removed Estuardo Aguilar-Cordova and Laura Aguilar from their roles as officers of the Company, without cause under their respective employment agreements with the Company, with such termination expected to be effective on February 7, 2022.
Estuardo Aguilar-Cordova was removed as officer at Candel Therapeutics, Inc..
Action
removed
Role
officer
Exact text from the filing
On January 28, 2022, Candel Therapeutics, Inc. (the “Company”) removed Estuardo Aguilar-Cordova and Laura Aguilar from their roles as officers of the Company, without cause under their respective employment agreements with the Company, with such termination expected to be effective on February 7, 2022.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.